Acute Pain
Volume 8, Issue 3 , Pages 95-97 , October 2006

Are COX-2 selective inhibitors safe for post-operative pain treatment? … Yes and no

Received 11 July 2006

References 

  1. Blower AL, Brooks A, Fenn GC, Hill A, Pearce MY, Morant S, et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther. 1997;11:283–291
  2. Food and Drug Administration . FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAIDs). Rockville, MD: FDA; 2005;
  3. EMEA press release: European medicines agency concludes action on COX-2 inhibitors EMEA Doc. Ref. EMEA/207766/2005.
  4. Nussmeier NA, Whelton A, Brown MT, Langford RM, Joshi G, Verburg KM. Safety of parecoxib and valdecoxib in the treatment of pain following coronary artery bypass surgery. N Engl J Med. 2005;352:1081–1091
  5. Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481–1492
  6. Nussmeier NA, Whelton A, Brown MT, Langford RM, Joshi G, Singla NK, et al. Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery. Anesthesiology. 2006;104(3):518–526
  7. Schug S. Poster presentation. Madrid, Spain: ESA; 2006;
  8. Ketorolac data sheet. ABPI Compendium; 2004;
  9. Moiniche S, Romsing J, Dahl JB, Tramer MR. Nonsteroidal anti-inflammatory drugs and the risk of operative site bleeding after tonsillectomy: a quantitative systematic review. Anesth Analg. 2003;96(1):68–77

PII: S1366-0071(06)00074-X

doi: 10.1016/j.acpain.2006.07.002

Acute Pain
Volume 8, Issue 3 , Pages 95-97 , October 2006

Article Tools